Search Results - "Kolkhof, Peter"

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine by Agarwal, Rajiv, Kolkhof, Peter, Bakris, George, Bauersachs, Johann, Haller, Hermann, Wada, Takashi, Zannad, Faiez

“…Abstract This review covers the last 80 years of remarkable progress in the development of mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of…”
Get full text

Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease by Kintscher, Ulrich, Bakris, George L., Kolkhof, Peter

“…Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline‐oriented drug therapy for cardiovascular diseases such as chronic heart failure with…”
Get full text

Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy by Kolkhof, Peter, Joseph, Amer, Kintscher, Ulrich

“…During the recent 30 years, there has been a dramatic increase in knowledge about the role of aldosterone and the mineralocorticoid receptor (MR) in the…”
Get full text

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes by Bakris, George L, Agarwal, Rajiv, Anker, Stefan D, Pitt, Bertram, Ruilope, Luis M, Rossing, Peter, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Joseph, Amer, Filippatos, Gerasimos

“…In this double-blind trial, patients with chronic kidney disease and type 2 diabetes were randomly assigned to receive the nonsteroidal, selective…”
Get full text

Nonsteroidal antagonists of the mineralocorticoid receptor by Kolkhof, Peter, Nowack, Christina, Eitner, Frank

“…PURPOSE OF REVIEWThe broad clinical use of steroidal mineralocorticoid receptor antagonists (MRAs) is limited by the potential risk of inducing hyperkalemia…”
Get full text

The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling by Barrera-Chimal, Jonatan, Estrela, Gabriel R, Lechner, Sebastian M, Giraud, Sébastien, El Moghrabi, Soumaya, Kaaki, Shiem, Kolkhof, Peter, Hauet, Thierry, Jaisser, Frédéric

“…Acute kidney injury induced by ischemia/reperfusion is an independent risk factor for chronic kidney disease. Macrophage recruitment plays an essential role…”
Get more information

The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling by Lavall, Daniel, Jacobs, Nadine, Mahfoud, Felix, Kolkhof, Peter, Böhm, Michael, Laufs, Ulrich

“…[Display omitted] Mineralocorticoid receptor (MR) overactivation promotes cardiac fibrosis. We studied the ability of the non-steroidal MR antagonist…”
Get full text

Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity by Grune, Jana, Beyhoff, Niklas, Smeir, Elia, Chudek, Remigiusz, Blumrich, Annelie, Ban, Zsofia, Brix, Sarah, Betz, Iris R, Schupp, Michael, Foryst-Ludwig, Anna, Klopfleisch, Robert, Stawowy, Philipp, Houtman, René, Kolkhof, Peter, Kintscher, Ulrich

“…Mineralocorticoid receptor antagonists (MRAs) reduce morbidity and mortality in chronic heart failure. Novel nonsteroidal MRAs are currently developed and need…”
Get full text

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems by Kolkhof, Peter, Lawatscheck, Robert, Filippatos, Gerasimos, Bakris, George L

“…Perception of the role of the aldosterone/mineralocorticoid receptor (MR) ensemble has been extended from a previously renal epithelial-centered focus on…”
Get full text

Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside by Kolkhof, Peter, Jaisser, Frederic, Kim, So-Young, Filippatos, Gerasimos, Nowack, Christina, Pitt, Bertram

“…Characterization of mice with cell-specific deletion or overexpression of the mineralocorticoid receptor (MR) shed a new light on its role in health and…”
Get more information

Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics by Barrera-Chimal, Jonatan, Kolkhof, Peter, Lima-Posada, Ixchel, Joachim, Alexandre, Rossignol, Patrick, Jaisser, Frederic

“…Mineralocorticoid receptor (MR) antagonists (MRAs) provide cardiorenal protection. However steroidal MRAs might induce hyperkalemia and sex hormone-related…”
Get more information

Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis by Droebner, Karoline, Pavkovic, Mira, Grundmann, Manuel, Hartmann, Elke, Goea, Laura, Nordlohne, Johannes, Klar, Jürgen, Eitner, Frank, Kolkhof, Peter

“…The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical…”
Get more information

Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro by Gerisch, Michael, Heinig, Roland, Engelen, Anna, Lang, Dieter, Kolkhof, Peter, Radtke, Martin, Platzek, Johannes, Lovis, Kai, Rohde, Gabriele, Schwarz, Thomas

“…Mass balance and biotransformation of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, were investigated in four healthy male volunteers…”
Get full text

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes by Agarwal, Rajiv, Ruilope, Luis M., Ruiz-Hurtado, Gema, Haller, Hermann, Schmieder, Roland E., Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Rossing, Peter, Lambelet, Marc, Nowack, Christina, Kolkhof, Peter, Joseph, Amer, Bakris, George L

“…Finerenone is a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life. Its effects on cardiorenal outcomes were thought to be…”
Get full text

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1 by Amazit, Larbi, Le Billan, Florian, Kolkhof, Peter, Lamribet, Khadija, Viengchareun, Say, Fay, Michel R., Khan, Junaid A., Hillisch, Alexander, Lombès, Marc, Rafestin-Oblin, Marie-Edith, Fagart, Jérôme

“…Aldosterone regulates sodium homeostasis by activating the mineralocorticoid receptor (MR), a member of the nuclear receptor superfamily. Hyperaldosteronism…”
Get full text

Antagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells by Le Billan, Florian, Perrot, Julie, Carceller, Elena, Travers, Simon, Viengchareun, Say, Kolkhof, Peter, Lombès, Marc, Fagart, Jérôme

“…Aldosterone, the main mineralocorticoid hormone in humans, plays a pivotal role in the control of water and salt reabsorption via activation of the…”
Get full text

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial by Bakris, George L, Agarwal, Rajiv, Anker, Stefan D, Pitt, Bertram, Ruilope, Luis M, Nowack, Christina, Kolkhof, Peter, Ferreira, Anna C, Schloemer, Patrick, Filippatos, Gerasimos

“…Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying…”
Get more information

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy by Jerome, Jack R, Deliyanti, Devy, Suphapimol, Varaporn, Kolkhof, Peter, Wilkinson-Berka, Jennifer L

“…Vision loss in diabetic retinopathy features damage to the blood-retinal barrier and neovascularization, with hypertension and the renin-angiotensin system…”
Get full text

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development by Kolkhof, Peter, Bärfacker, Lars

“…The cDNA of the mineralocorticoid receptor (MR) was cloned 30 years ago, in 1987. At that time, spirolactone, the first generation of synthetic steroid-based…”
Get full text

Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1 by Barrera-Chimal, Jonatan, André-Grégoire, Gwennan, Nguyen Dinh Cat, Aurelie, Lechner, Sebastian M, Cau, Jérôme, Prince, Sonia, Kolkhof, Peter, Loirand, Gervaise, Sauzeau, Vincent, Hauet, Thierry, Jaisser, Frédéric

“…AKI is a frequent complication in hospitalized patients. Unfortunately, there is no effective pharmacologic approach for treating or preventing AKI. In…”
Get full text